Latest News
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
29 October 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Thursday that it has received European Medicines Agency (EMA) validation for two marketing authorisation applications covering single-pill triple-combination ...
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
29 October 2026 - Biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) said on Thursday that it has signed a binding exclusive negotiation agreement with Japanese clinical-stage biotechnology company TMS Co Ltd to negotiate a definitiv...
Formation Bio establishes USD600m debut fund for drug development
29 October 2026 - Formation Bio, a New York-based, AI-native pharmaceutical company, announced on Wednesday the Formation Bio Drug Development Accelerator Fund with USD600m in capital commitments.This fund is designed to expand the company's por...
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
29 October 2026 - Chinese pharmaceutical company Ascletis Pharma Inc (HKEX:1672) on Wednesday reported positive topline results from its US Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of ...
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
28 October 2026 - Computational chemistry company Evogene Ltd (NASDAQ: EVGN) (TASE: EVGN) announced on Wednesday that it has selected acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery programme...